MedTrace Logo

SUBLOCADE Rapid Initiation Extension Study

NCT04060654 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2025-03-25

Study results available
· View outcomes & findings →

Summary

A single center, open-label SUBLOCADE treatment extension study in which up to 25 participants diagnosed with moderate to severe opioid use disorder (OUD) could be enrolled.

Conditions

  • Opioid Use Disorder, Severe
  • Opioid Use Disorder, Moderate

Interventions

DRUG

Sublocade

SUBLOCADE to be administered approximately every 4 weeks per local standard of care

Sponsors & Collaborators

  • Indivior Inc.

    lead INDUSTRY

Principal Investigators

  • Michael Hassman · Hassman Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-21
Primary Completion
2020-05-15
Completion
2020-05-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04060654 on ClinicalTrials.gov